Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Deconstructing the RAGE signaling maze: the molecular key to opening a new dimension of ovarian anti-aging

Bai X., Zhang G., Xiao X., Zeng Q., Zhao Y., Wang P.

Narrative Review on Chronic Inflammation, published in Exp Mol Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Exp Mol Med (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42009954
PMCID
PMC13144357
DOI
10.1038/s12276-026-01678-3

Abstract (original English)

The ovaries are vital components of the female reproductive system. Ovarian aging, driven by oxidative stress, chronic inflammation and hormonal dysregulation, severely compromises female fertility. The receptor for advanced glycation end products (RAGE) serves as a critical regulator of ovarian physiology and pathology. linking metabolic dysfunction to reproductive decline. This Review synthesizes evidence that RAGE hyperactivation, during the process of ovarian aging, disrupts folliculogenesis, granulosa cell function and steroidogenesis via MAPK-ERK, PI3K-AKT-mTOR and NF-κB pathways, exacerbating conditions such as premature ovarian failure, polycystic ovary syndrome and ovarian cancer. Furthermore, we summarizes existing therapeutic strategies targeting RAGE and underscores their potential in mitigating ovarian aging and treating ovarian pathologies, providing novel perspectives for preserving female reproductive capacity. We highlight therapeutic strategies targeting RAGE, including small-molecule inhibitors (Azeliragon and FPS-ZM1), soluble RAGE decoys and natural compounds, which show promise in restoring ovarian reserve and hormonal balance in preclinical models. These interventions mitigate advanced glycation end products (AGE)-RAGE-induced damage, offering novel avenues to preserve fertility. Beyond reproductive health, RAGE's role in aging and metabolic disorders und

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
OvaryAnimalsHumansSignal TransductionAgingFemaleReceptor for Advanced Glycation End ProductsGlycation End Products, Advanced

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research